Which Beta-Blocker is Best for Patients with Heart Failure? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology December 17,

Slides:

Advertisements

Similar presentations

The prevalence of use of beta- blockers in secondary prevention of myocardial infarctions in patients hospitalized 1 Institute of Epidemiology and biostatistics,

Advertisements

Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial

Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.

Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)

Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-

Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2010.

EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C FOR SEVERE SEPSIS (PROWESS) GORDONR. BERNARD, M.D. et al. The New England Journal of Medicine.

Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.

“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.

Journal Club Alcohol and Health: Current Evidence January-February 2005.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

analysis from the SHIFT study

“Hospital Performance Recognition with the Get with the Guidelines Program and Mortality for Acute Myocardial Infarction and Heart Failure Paul A Heidenreich,

Spring 2015 ETM 568 Callier, Demers, Drabek, & Hutchison Carter, E. J., Pouch, S. M., & Larson, E. L. (2014). The relationship between emergency department.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Clinical Impact of Adherence to Pharmacotherapeutic Guidelines on the Outcome in Patients with Chronic Heart Failure Suntheep Batra, M.Pharm Department.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Telephone Triage for Stroke by Ambulance Services in the U.K. Summary and Comment by J. Stephen Bohan, MD, MS, FACP, FACEP Published in Journal Watch Emergency.

Benefits of Urgent Evaluation and Treatment for TIA and Minor Stroke Summary and Comment by Kristi L. Koenig, MD, FACEP Published in Journal Watch Emergency.

Memory in Elders: Food for Thought Summary and Comment by Jonathan Silver, MD Published in Journal Watch Psychiatry March 9, 2009Journal Watch Psychiatry.

Thomas S. Rector, PhD, Inder S. Anand, MD, David Nelson, PhD, Kristine Ensrud, MD and Ann Bangerter, MS CHF QUERI NETWORK November 8, 2007 VA Medical Center,

Clinical Trial Results. org Relationship Between Adherence to Evidence- Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction.

Emergency Intubations for Trauma: One Center's Experience Summary and Comment by Ron M. Walls, MD, FRCPC, FAAEM Published in Journal Watch Emergency Medicine.

AEDs Do Not Improve Survival from In-Hospital Arrest Summary and Comment by Daniel J. Pallin, MD, MPH Dr. Pallin is an attending physician in the Department.

Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

Better Outcomes at Level I vs. Level II Trauma Centers Summary and Comment by John A. Marx, MD, FAAEM, FACEP Published in Journal Watch Emergency Medicine.

Normal ECG During Chest Pain Does Not Rule Out ACS Summary and Comment by Diane M. Birnbaumer, MD, FACEP Published in Journal Watch Emergency Medicine.

Influence of Comorbid Depression and Antidepressant Treatment on Mortality for Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease by SSDI-eligibility.

Depression and Parkinson Disease: An Old Drug Still Works (Better) Summary and Comment by Jonathan Silver, MD Published in Journal Watch Psychiatry February.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Does the Choice of Antihypertensive Agent Affect Risk for AFib? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology February.

Decreasing Incidence of Cardiogenic Shock Summary and Comment by J. Stephen Bohan, MD, MS, FACP, FACEP Published in Journal Watch Emergency Medicine December.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.

Prehospital ECGs for Acute Coronary Syndromes Summary and Comment by Aaron E. Bair, MD, MSc, FAAEM, FACEP Published in Journal Watch Emergency Medicine.

Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Finding the Evidence Approximately 8,000 completed references are added to MEDLINE each week (over 400,000 added per year) Too much for any one person.

Adenosine for Regular Wide-Complex Tachycardia Summary and Comment by Daniel J. Pallin, MD, MPH Published in Journal Watch Emergency Medicine October 9,

Emergency Cricothyrotomy: Comparing Four Methods Summary and Comment by Aaron E. Bair, MD, MSc, FAAEM, FACEP Published in Journal Watch Emergency Medicine.

Bigger Waist Means Higher Asthma Risk Summary and Comment by Wendy S. Biggs, MD Published in Journal Watch Women's Health September 24, 2009Journal Watch.

Discharge Instructions: Understanding the Misunderstandings Summary and Comment by Richard D. Zane, MD, FAAEM Published in Journal Watch Emergency Medicine.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.

Short Sleep Duration as a Predictor of Cardiovascular Events Summary and Comment by Jamaluddin Moloo, MD, MPH Published in Journal Watch General Medicine.

The Burden of Angina Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology March 25, 2009Journal Watch Cardiology In.

Induced Hypothermia After VF Cardiac Arrest Improves Outcomes Summary and Comment by Kristi L. Koenig, MD, FACEP Published in Journal Watch Emergency Medicine.

Do IV Meds Matter in Out-of-Hospital Cardiac Arrest? Summary and Comment by John A. Marx, MD, FAAEM Published in Journal Watch Emergency Medicine December.

A Resuscitation Protocol That Minimizes Hands- Off Time Improves Survival Summary and Comment by Aaron E. Bair, MD, MSc, FAAEM, FACEP Published in Journal.

Increased mortality among patients taking digoxin—analysis from the AFFIRM study or Lack of evidence of increased mortality among patients with atrial.

Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.

Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,

JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS

Cocaine-Related Chest Pain: The Year After

Insights from the NCDR® STS/ACC TVT Registry.

Valsartan in Acute Myocardial Infarction Trial Investigators

O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.

Global Registry of Acute Coronary Events: GRACE

Section III: Neurohormonal strategies in heart failure

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Orly Vardeny et al. JCHF 2016;4:

Presentation transcript:

Which Beta-Blocker is Best for Patients with Heart Failure? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology December 17, 2008Journal Watch Cardiology Evidence of efficacy might not be the most important factor to consider. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

Covering Kramer JM et al. Comparative effectiveness of β-blockers in elderly patients with heart failure. Arch Intern Med 2008 Dec 8; 168:2422. Go AS et al. Comparative effectiveness of different β-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med 2008 Dec 8; 168:2415. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

Background Treatment of systolic heart failure with beta-blockers has been shown to reduce cardiovascular morbidity and mortality, but which beta-blocker to use is the subject of debate. In two independent observational studies, investigators assessed the comparative effectiveness of different beta-blockers in patients with heart failure. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

The Research In the first study, the authors identified nearly 12,000 patients aged 65 or older in North Carolina Medicaid and Medicare records from 2001 through 2004 who had had at least one hospitalization for heart failure. The researchers assessed mortality from 30 days to 1 year after discharge in patients taking the evidence-based beta-blockers (EBBBs) carvedilol, metoprolol succinate, and bisoprolol (23%); in patients taking non–evidence-based beta-blockers (non-EBBBs; 18%); and in patients taking no beta-blockers (59%). Propensity adjustment resulted in well-balanced baseline characteristics among the groups. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

The Research In both unadjusted and adjusted analyses, 1-year mortality was significantly higher in the group receiving no beta-blockers (28.3%, adjusted) than in either the non-EBBB group (22.8%) or the EBBB group (24.2%); the difference between the death rates in the non- EBBB and EBBB groups was statistically nonsignificant. Significantly more rehospitalizations occurred in patients receiving EBBBs than in those receiving either no beta-blockers or non- EBBBs. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

The Research In the second study, investigators used data from two large U.S. healthcare systems to evaluate more than 11,000 patients (mean age, 74) who survived hospitalization for heart failure between 2001 and At discharge or during 12 months of follow-up, 7976 patients received beta-blockers: atenolol (38%), metoprolol tartrate (43%), carvedilol (12%), or others (7%). The mortality rate (per 100 person-years) was lowest in patients taking carvedilol (17.7%), followed by atenolol (20.1%), other beta- blockers (21.9%), and metoprolol tartrate (22.8%). Compared with patients taking atenolol, and adjusted for confounders and the propensity to receive carvedilol, the risk for death was significantly increased in those taking metoprolol tartrate (hazard ratio, 1.16) or no beta-blockers (HR, 1.63), but not in those taking carvedilol. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

Comment The results of these two studies underscore the importance of following guideline recommendations to use beta-blockers in all patients with heart failure caused by LV systolic dysfunction, regardless of their age. The findings suggest that metoprolol tartrate is not as effective as is atenolol or carvedilol. Whether evidence-based beta-blockers (e.g., carvedilol) are generally superior to non–evidence-based beta-blockers (e.g., atenolol) can be conclusively determined only by large-scale randomized trials. CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society

About Journal Watch Journal Watch helps physicians and allied heath professionals save time and stay informed by providing brief, clearly written, clinically focused perspectives on the medical developments that affect practice. Journal Watch is an independent, trustworthy source, from the publishers of the New England Journal of Medicine. These slides were derived from Journal Watch Cardiology.Journal Watch Cardiology The best way to stay informed with Journal Watch, is through our alerts. To sign up, visit the My Alerts page.My Alerts page CopyrightCopyright © Massachusetts Medical Society. All rights reserved.Massachusetts Medical Society